Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

FDA approves first medical device system to adjust artificial lens after cataract surgery

RxSight has secured approval from the US Food and Drug Administration (FDA) for its light adjustable lens and light delivery device (LDD) to treat patients with pre-existing astigmatism of ≥ 0.75 diopters undergoing cataract surgery.

RxSight’s light adjustable lens are claimed to be the first and only FDA approved intraocular lens (IOL), which can be adjusted post-operatively to improve uncorrected visual acuity.

The firm’s light adjustable lens allows doctors and patients to predictably enhance optimize vision after cataract surgery through an office based IOL enhancement.

The approval has been granted based on results of the US randomized and pivotal study, which compared light adjustable lens against commercially available monofocal lens in 600 patients with pre-existing astigmatism at 17 investigational sites..

According to the company, patients receiving the light adjustable lens, followed by light treatment with the LDD, achieved UCVA of 20/20 or better at six months postoperatively at approximately twice the rate of patients receiving monofocal lens.

The approved device enables correction of up to two diopters of post-operative sphere and -0.75 to -2 diopters of residual postoperative refractive cylinder.

In addition, the company has secured CE mark for an expanded cylinder range (-0.5 to -3.00 diopters).

 RxSight chief commercial officer Eric Weinberg said: “This is an exciting opportunity for patients, surgeons and referring optometrists who have been awaiting a true breakthrough in refractive IOL technology.

“We are very grateful to all of those who have been involved in this effort, including the outstanding clinical coordinators, study investigators and their staff who facilitated the study, as well as the RxSight and FDA personnel who prepared and reviewed the regulatory submission.”


Image: The FDA campus in New Hampshire Ave, Silver Spring, Maryland. Photo: courtesy of The U.S. Food and Drug Administration.